111 Inc

詳細情報 111 Inc 企業名

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

企業情報

企業コードYI

会社名111 Inc

上場日Sep 12, 2018

最高経営責任者「CEO」Mr. Junling Liu

従業員数1238

証券種類Depository Receipt

決算期末Sep 12

本社所在地3-4/F, No.295 Zuchongzhi Road

都市SHANGHAI

証券取引所NASDAQ Global Market Consolidated

国China

郵便番号201203

電話番号862120536666

ウェブサイトhttp://corporate.111.com.cn/

企業コードYI

上場日Sep 12, 2018

最高経営責任者「CEO」Mr. Junling Liu

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Junling Liu

Co-Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Gang Yu, Ph.D.

Executive Co-Chairman of the Board, Co-Founder

--

Mr. Yang (Luke) Chen

Director

--

Mr. Jun Luo

Independent Director

--

Mr. Jian (David) Sun

Independent Director

--

Mr. Nee Chuan Teo, CPA

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Junling Liu

Co-Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Gang Yu, Ph.D.

Executive Co-Chairman of the Board, Co-Founder

--

Mr. Yang (Luke) Chen

Director

--

Mr. Jun Luo

Independent Director

--

Mr. Jian (David) Sun

Independent Director

--

Mr. Nee Chuan Teo, CPA

Independent Director

--

収益内訳

通貨: CNY更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

事業別CNY

会社名

収益

比率

Product Revenues

3.51B

99.44%

Service Revenues

19.70M

0.56%

データなし

事業別

地域別

事業別CNY

会社名

収益

比率

Product Revenues

3.51B

99.44%

Service Revenues

19.70M

0.56%

株主

更新時刻: Fri, Aug 15

株主統計

種類

株主統計

比率

ClearVue Partners

15.64%

First Pharmacia International

8.57%

6 Dimensions Capital Ltd.

7.15%

Zall Capital Ltd

2.82%

Tongyi Investment Holding Ltd

2.13%

他の

63.69%

株主統計

比率

ClearVue Partners

15.64%

First Pharmacia International

8.57%

6 Dimensions Capital Ltd.

7.15%

Zall Capital Ltd

2.82%

Tongyi Investment Holding Ltd

2.13%

他の

63.69%

種類

株主統計

比率

Corporation

15.84%

Private Equity

15.64%

Venture Capital

7.15%

Investment Advisor

0.50%

Hedge Fund

0.26%

Investment Advisor/Hedge Fund

0.22%

Research Firm

0.11%

他の

60.29%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

48

1.99M

39.33%

-416.92K

2025Q1

49

2.00M

39.53%

-387.91K

2024Q4

51

2.26M

44.72%

+133.67K

2024Q3

43

1.99M

39.36%

-280.22K

2024Q2

45

2.17M

42.88%

-87.92K

2024Q1

52

2.15M

42.65%

-125.45K

2023Q4

54

2.16M

44.89%

-28.04K

2023Q3

57

2.15M

44.81%

-47.43K

2023Q2

64

2.05M

43.37%

+895.26K

2023Q1

77

2.20M

46.58%

+971.22K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

ClearVue Partners

792.41K

15.64%

--

Feb 27, 2024

First Pharmacia International

434.53K

8.57%

--

Mar 31, 2025

6 Dimensions Capital Ltd.

362.30K

7.15%

--

Feb 27, 2024

Zall Capital Ltd

143.12K

2.82%

--

Feb 27, 2024

Tongyi Investment Holding Ltd

107.78K

2.13%

--

Feb 27, 2024

Allied China Investment Ltd

94.97K

1.87%

--

Feb 27, 2024

J.P. Morgan Trust Company of Delaware

22.17K

0.44%

--

Feb 27, 2024

Renaissance Technologies LLC

12.81K

0.25%

-531.00

-3.98%

Mar 31, 2025

Connor, Clark & Lunn Investment Management Ltd.

11.34K

0.22%

+11.34K

--

Mar 31, 2025

詳細を見る

5.220USD

111 Inc

5.220

概要

企業名

金融

分析